ArticleReumatologia clinica2021
Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia.
Article in Reumatologia clinica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04540926 (Utility of Low Doses of Corticosteroids and Cyclosporine Combined With Enoxaparin, in Patients With COVID-19 Pneumonia at the ISSSTE Regional Hospital, Puebla, During the Contingency Period Due to the SARS-Cov2 Pandemic), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Utility of Low Doses of Corticosteroids and Cyclosporine Combined With Enoxaparin, in Patients With COVID-19 Pneumonia at the ISSSTE Regional Hospital, Puebla, During the Contingency Period Due to the SARS-Cov2 Pandemic
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Combined Therapy of Ciclosporin Plus Favipiravir in the Management of Patients with Severe COVID-19, not Responding to Dexamethasone: A non-Controlled Prospective Trial.International immunopharmacology · 2021Trial
- Cyclosporine A plus low-dose steroid treatment in COVID-19 improves clinical outcomes in patients with moderate to severe disease: A pilot study.Journal of internal medicine · 2021Trial
- Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients.Molecular therapy. Methods & clinical development · 2022Article
- Calcineurin Inhibitors and COVID-19.Reumatologia clinica · 2022Article
- Clinical and Molecular Relationships between COVID-19 and Feline Infectious Peritonitis (FIP).Viruses · 2022Review
- Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.Microbiology spectrum · 2022Article
- Promising Neutrophil-Associated Biomarkers in Lung Diseases of Patients with Antisynthetase Syndrome and Dermatomyositis.Journal of immunology research · 2022Article
- [Management of aplastic anemia during the phase of defervescence of the COVID-19 pandemic].Medicina clinica · 2021Article
- A Multidisciplinary Approach to Coronavirus Disease (COVID-19).Molecules (Basel, Switzerland) · 2021Review
- Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2021Review
- Review
- COVID-19: Characteristics and Therapeutics.Cells · 2021Review
- Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19?Frontiers in medicine · 2021Review
- Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches.Bioorganic chemistry · 2021Review
- The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options.Microbial pathogenesis · 2021Review
- Cyclosporine A and COVID19 - The COQUIMA cohort.EClinicalMedicine · 2021Article
- Methylprednisolone Pulses Plus Tacrolimus in Addition to Standard of Care vs. Standard of Care Alone in Patients With Severe COVID-19. A Randomized Controlled Trial.Frontiers in medicine · 2021Article
- Calcineurin Inhibitors and COVID-19.Reumatologia clinica · 2020Article
- COVID-19: An Archetype Innate Immunity Reaction and Modes of Treatment.Mediterranean journal of rheumatology · 2020Review
- The current understanding and potential therapeutic options to combat COVID-19.Life sciences · 2020Review
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.